



## Rain Therapeutics to Present at Upcoming Investor Conferences

December 21, 2021

NEWARK, Calif., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), ("Rain"), a late-stage company developing precision oncology therapeutics, today announced that Avanish Vellanki, co-founder, chairman and chief executive officer of Rain, will provide a corporate overview at the JP Morgan Chase 40<sup>th</sup> Annual Healthcare Conference and at the H.C. Wainwright Bioconnect Conference, both conferences being held virtually January 10-13, 2022.

Additional details can be found below:

**Conference:** JP Morgan Chase 40<sup>th</sup> Annual Healthcare Conference

**Date and Time:** Thursday, January 13, 2022 at 11:15 a.m. ET

**Location:** [Webcast Link](#) - or at the company's website ( [click here](#) )

**Conference:** H.C. Wainwright Bioconnect Conference

**Date and Time:** Prerecorded presentation will be available beginning Monday, January 10, 2022 at 7:00 a.m. ET

**Location:** [Webcast Link](#) - or at the company's website ( [click here](#) )

Replay of the corporate overview presentation will be available by visiting the "[Events & Presentations](#)" section of the Rain website after the conclusion of the presentation and will be archived on the Rain website for 30 days.

### About Rain Therapeutics Inc.

Rain Therapeutics Inc. is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will most likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors' underlying genetics rather than histology. Rain's lead product candidate, milademetan, is a small molecule, oral inhibitor of MDM2, which is oncogenic in numerous cancers. In addition to milademetan, Rain is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.

### Media Contact

Jordyn Temperato

LifeSci Communications

[jtemperato@lifescicomms.com](mailto:jtemperato@lifescicomms.com)

### Investor Contact

Bob Yedid

LifeSci Advisors

+1.646.597.6989

[bob@lifesciadvisors.com](mailto:bob@lifesciadvisors.com)



Source: Rain Therapeutics